DiPaola R S, Zhang H, Lambert G H, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer[J]. N Engl J Med, 1998, 339(12): 785.
[3]
Kosty M P. PC-SPES: hope or hype?[J]. J Clin Oncol, 2004, 22(18): 3657.
[4]
Hsieh T C, Wu J M. Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells[J]. Int J Oncol, 2002, 20(3): 583.
Schmidt M, Polednik C, Gruensfelder P, et al. The effects of PC-SPES on chemosensitive and chemoresistant head and neck cancer cells and primary mucosal keratinocytes[J]. Oncol Rep, 2009, 21(5): 1297.
[7]
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9.
Sonpavde G, Sternberg C N. Contemporary management of metastatic castration-resistant prostate cancer[J]. Curr Opin Urol, 2011, 21(3): 241.
[10]
Reid A H, Attard G, Danila D, et al. A multicenter phase Ⅱ study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)[J]. J Clin Oncol, 2009, 27(15): 5047.
[11]
Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13): 1187.
[12]
Heemers H V, Tindall D J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex[J]. Endocrine Rev, 2007, 28(7): 778.
[13]
Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer[J]. Cell, 2009, 138(2): 245.
[14]
Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target[J]. J Molecular Endocrinol, 2011, 47(1): R25.
[15]
Niu Y, Yeh S, Miyamoto H, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation[J]. Cancer Res, 2008, 68(17): 7110.
[16]
Saxena P, Trerotola M, Wang T, et al. PSA regulates androgen receptor expression in prostate cancer cells[J]. Prostate, 2012, 72(7): 769.
[17]
Haag P, Bektic J, Bartsch G, et al. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells[J]. J Steroid Biochem Mol Biol, 2005, 96(3): 251.
[18]
Wen S, Niu Y, Lee S O, et al. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death[J]. Cancer Treatment Rev, 2014, 40(1): 31.
[19]
Kadowaki Y, Chari N S, Teo A E K, et al. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells[J]. Apoptosis, 2011, 16(6): 627.
[20]
Yang H, Murthy S, Sarkar F H, et al. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells[J]. J Cell Physiol, 2008, 217(3): 569.
